Research programme: vascular endothelial growth factor receptor antagonists - PhiloGene
Alternative Names: PLG101; PLG201; PLG202Latest Information Update: 15 Apr 2019
At a glance
- Originator PhiloGene
- Developer Alcon; PhiloGene
- Class Cytokines; Proteins
- Mechanism of Action Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic retinopathy; Solid tumours
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 26 Aug 2010 Alcon has been acquired by Novartis
- 07 Aug 2009 Preclinical development is ongoing in Israel and the US